| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF-1 receptor |
| Clinical data | |
| Routes of administration | IV |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6500H10052N1724O2036S44 |
| Molar mass | 146336.59 g·mol−1 |
  (what is this?) (verify) | |
Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors.[1][2]
This drug was developed by ImClone Systems, since acquired by Eli Lilly, using phage display technology from Dyax.[citation needed]
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the ligand IGF-1 and subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.[3]
- ^ "Statement On A Nonproprietary Name Adopted – Cixutumumab" (PDF). The USAN Council. American Medical Association.
- ^ McKian KP, Haluska P (July 2009). "Cixutumumab". Expert Opinion on Investigational Drugs. 18 (7): 1025–33. doi:10.1517/13543780903055049. PMC 2939377. PMID 19548856.
- ^ "Cixutumumab". National Cancer Institute. 2011-02-02.